

The emerging roles of inositol pyrophosphates in eukaryotic cell physiology

SWARNA GOWRI THOTA^{1,2} and RASHNA BHANDARI^{1,*}

¹Laboratory of Cell Signalling, Centre for DNA Fingerprinting and Diagnostics, Hyderabad 500 001, India

²Graduate Studies, Manipal University, Manipal 576 104, India

*Corresponding author (Email, rashna@cdfd.org.in)

Inositol pyrophosphates are water soluble derivatives of inositol that contain pyrophosphate or diphosphate moieties in addition to monophosphates. The best characterised inositol pyrophosphates, are IP₇ (diphosphoinositol pentakisphosphate or PP-IP₅), and IP₈ (bisdiphosphoinositol tetrakisphosphate or (PP)₂-IP₄). These energy-rich small molecules are present in all eukaryotic cells, from yeast to mammals, and are involved in a wide range of cellular functions including apoptosis, vesicle trafficking, DNA repair, osmoregulation, phosphate homeostasis, insulin sensitivity, immune signalling, cell cycle regulation, and ribosome synthesis. Identified more than 20 years ago, there is still only a rudimentary understanding of the mechanisms by which inositol pyrophosphates participate in these myriad pathways governing cell physiology and homeostasis. The unique stereochemical and bioenergetic properties these molecules possess as a consequence of the presence of one or two pyrophosphate moieties in the vicinity of densely packed monophosphates are likely to form the molecular basis for their participation in multiple signalling and metabolic pathways. The aim of this review is to provide first time researchers in this area with an introduction to inositol pyrophosphates and a comprehensive overview on their cellular functions.

[Thota SG and Bhandari R 2015 The emerging roles of inositol pyrophosphates in eukaryotic cell physiology. *J. Biosci.* **40** 593–605] DOI 10.1007/s12038-015-9549-x

1. Structure of inositol and inositol phosphates

Inositol or cyclohexane-1,2,3,4,5,6-hexol is a carbohydrate with the formula C₆H₁₂O₆, and occurs widely in nature. It has nine possible stereoisomers, of which *myo*-inositol is the most abundant form in living cells (figure 1A). Numbering of carbon atoms on the inositol ring is counterclockwise, as recommended by the Nomenclature Committee of the International Union of Biochemistry (NC-IUB) (1989a, b). Instead of using the Haworth projection (figure 1A), it is easier to understand *myo*-inositol nomenclature by comparing the thermodynamically stable chair conformation (figure 1B) to a turtle (figure 1C), as suggested by Bernard Agranoff (Agranoff 1986, 2009; Irvine and Schell 2001). The head of the Agranoff turtle is the hydroxyl group at position 2, which is axial

(perpendicular to the plane of the ring), and the flippers and tail denote all 5 other hydroxyl groups, which are equatorial (in the plane of the ring). Inositol phosphates are synthesised by replacing the hydroxyl groups with phosphate groups on *myo*-inositol, and the nomenclature follows Arganoff's turtle. There are 63 mathematically predicted stereoisomers (including 24 pairs of enantiomers and 15 mesomers) for the inositol ring that is substituted with 1 to 6 monophosphate groups (Barker *et al.* 2009; Wundenberg and Mayr 2012), and many are found in nature. The six hydroxyl groups on the inositol ring are replaced with monophosphates in inositol hexakisphosphate (IP₆) (figure 1D). It is pertinent to note that the correct IUPAC abbreviation for *myo*-inositol is 'Ins', but it is commonly abbreviated as 'I'. In this review we have chosen the latter, as it is simpler to vocalize.

Keywords. Bisdiphosphoinositol tetrakisphosphate (IP₈); cell signalling; diphosphoinositol pentakisphosphate (IP₇); inositol hexakisphosphate (IP₆) kinase (IP6K); PP-IP₅ kinase (PPIP5K); pyrophosphorylation




Figure 1. Structure of inositol and inositol pyrophosphates. (A) Inositol conformation as suggested by Norman Haworth. (B and C) Inositol chair conformation (B) that is comparable with a turtle (C). (D, E and F) Structures of inositol hexakisphosphate (D), diphosphoinositol pentakisphosphate (E), and bis(diphosphoinositol) tetrakisphosphate (F).

The inositol pyrophosphates are a sub-family of inositol phosphates in which hydroxyl groups on the *myo*-inositol ring are substituted with both monophosphate and diphosphate (or pyrophosphate) moieties. Adding diphosphate groups on the ring further increases the number of stereoisomers of inositol phosphates. IP₇ (diphosphoinositol pentakisphosphate) consists of an inositol ring substituted with five monophosphates and one diphosphate moiety, and is therefore accurately referred to as PP-IP₅ (figure 1E), and IP₈ (bis(diphosphoinositol) tetrakisphosphate) which contains four monophosphate groups and two diphosphate groups, is (PP)₂-IP₄ (figure 1F).

2. Synthesis of inositol phosphates and pyrophosphates

In all eukaryotic cells, inositol is available in the cytosol as free inositol or its phosphorylated derivatives, and in the membrane as inositol head groups in phosphatidylinositol (PI) lipids. Inositol phosphate metabolism is well conserved from yeast to humans (Irvine and Schell 2001). In most eukaryotes, the inositol lipid phosphatidylinositol (4,5) bisphosphate, also known as PI(4,5)P₂, predominantly located on the plasma membrane (Varnai and Balla 2006) is the precursor for the synthesis of inositol phosphates and inositol pyrophosphates. The budding yeast, *S. cerevisiae*, possesses a simple metabolic pathway with a single enzyme for each step of inositol phosphate synthesis, whereas mammals have a larger repertoire of inositol phosphates and multiple isoforms of inositol phosphate synthesizing enzymes (figure 2). The inositol head group on phosphoinositide is accessible to the enzyme phosphoinositide-specific phospholipase-C (PLC)

(Yang *et al.* 2013), which cleaves PI(4,5)P₂ to generate inositol (1,4,5) trisphosphate (IP₃) and diacylglycerol (DAG) (figure 2). In mammalian cells, IP₃ released into the cytoplasm activates downstream effectors such as calcium channels on the endoplasmic reticulum leading to an increase in Ca²⁺ in the cytosol (Berridge *et al.* 2003). The single phosphoinositidase in yeast, Plc1 (Flick and Thorer 1993; Yoko-o *et al.* 1993) cleaves PI(4,5)P₂ to generate IP₃ (figure 2), but there is no calcium signalling activated by IP₃ in yeast. IP₃ is phosphorylated at positions 6 and 3 on the ring to form inositol (1,4,5,6) tetrakisphosphate (IP₄) and inositol (1,3,4,5,6) pentakisphosphate (IP₅) by a nuclear enzyme called Ipk2 (also called Arg82 or ArgRIII) in yeast (Odom *et al.* 2000; Saiardi *et al.* 2000b; Saiardi *et al.* 1999). In mammals and *Drosophila*, an additional enzyme family which is absent in yeast, called inositol-trisphosphate 3-kinases (IP3Ks or ITPKs) (Dewaste *et al.* 2000; Takazawa *et al.* 1990; Takazawa *et al.* 1991), convert I(1,4,5)P₃ to I(1,3,4,5)P₄, and the orthologue of Ipk2 called inositol polyphosphate multikinase (IPMK) (Saiardi *et al.* 1999) converts this form of IP₄ to IP₅ (figure 2). The yeast enzyme Ipk1 (York *et al.* 1999), predominantly found at the nuclear envelope, synthesizes inositol (1,2,3,4,5,6) hexakisphosphate (IP₆) from IP₅ by substituting the hydroxyl group at position 2 on the inositol ring, and in mammals the orthologue of Ipk1, inositol pentakisphosphate 2-kinase (IPPK) (Verbsky *et al.* 2002) generates IP₆. Mammals and plants possess an additional inositol phosphate kinase, called inositol (1,3,4) trisphosphate 5/6-kinase (ITPK1, not to be confused with ITPKs) (Wilson and Majerus 1996), which provides an alternate route to the generation of IP₅ (Verbsky *et al.* 2005). In this pathway, I(1,3,4,5)P₄ generated by IP3K is first dephosphorylated by a

5 phosphatase (Hansen *et al.* 1987) to I(1,3,4)P₃, and then phosphorylated by ITPK1 to I(1,3,4,6)P₄. This is acted upon by IPMK to make I(1,3,4,5,6)P₅.

IP₆ is the primary substrate for the synthesis of the major cellular inositol pyrophosphates, IP₇ and IP₈ [for other reviews on these molecules see (Azevedo *et al.* 2011; Barker and Berggren 2013; Barker *et al.* 2009; Bennett *et al.* 2006; Burton *et al.* 2009; Chakraborty *et al.* 2011; Koldobskiy and Snyder 2014; Saiardi 2012a, b; Shears 2007, 2009, 2015; Shears *et al.* 2011; Thomas and Potter 2014; Tsui and York 2010; Wilson *et al.* 2013; Wundenberg and Mayr 2012)]. IP₇ and IP₈ were discovered independently by Georg Mayr in collaboration with Len Stephens in *Dictyostelium discoideum* (Mayr *et al.* 1992; Stephens *et al.* 1993), and by Stephen Shears' group in pancreatoma cells (Menniti *et al.* 1993). Inositol hexakisphosphate kinase (IP6K) adds a β phosphate on the pre-existing α phosphate at position 5 on IP₆ to make 5PP-I(1,2,3,4,6)P₅ (5-IP₇) (Draskovic *et al.* 2008; Lin *et al.* 2009; Saiardi *et al.* 1999; Voglmaier *et al.* 1996) (figure 2). IP6K has three mammalian paralogs, IP6K1/2/3, which are expressed in different tissues and sub-cellular compartments (Saiardi *et al.* 1999; Saiardi *et al.* 2001; Thomas and Potter 2014). The single *S. cerevisiae* IP₆ kinase, Kcs1 (kinase C suppressor 1), was initially discovered as a suppressor of hyper-recombination caused by a mutation in protein kinase-C (Huang and Symington 1995), and later identified as an orthologue of mammalian IP6Ks (Saiardi *et al.* 1999). Sequence and structure based analyses reveal that IP3K, IPMK, and IP6K belong to the same inositol phosphate kinase superfamily, which possess N- and C-terminal lobes with an ATP binding cleft similar to protein kinases, and an additional inositol phosphate binding domain (Bennett *et al.* 2006; Gonzalez *et al.* 2004; Holmes and Jogl 2006; Miller and Hurley 2004; Saiardi *et al.* 1999; Wang *et al.* 2014a). A recent crystal structure of the *Entamoeba histolytica* IP6K suggests that this superfamily is likely to have evolved from an ancestor with hybrid IP3K-IP6K enzyme activity (Wang *et al.* 2014a). IP6Ks show low affinity towards ADP (K_m 1.34–1.7 mM) compared to IP₆ (K_m 0.6–3 μM) and ATP (K_m 0.7–1.4 mM) (Saiardi *et al.* 2000a; Wundenberg *et al.* 2014) and can also function as ATP synthases by donating a phosphate from 5-IP₇ or IP₆ to ADP *in vitro* (Voglmaier *et al.* 1992; Wundenberg *et al.* 2014). Under normal conditions, the physiological concentration of ATP and IP₆ are 1 mM and 10–100 μM respectively, and therefore IP6K drives synthesis of 5-IP₇ from IP₆ in cells. IP6Ks can modulate their enzymatic activity to either phosphorylation or dephosphorylation of IP₆, depending on the ATP/ADP ratio in cells. An increase in the ATP/ADP ratio results in synthesis of 5-IP₇ from IP₆, whereas a reduction in the ATP/ADP ratio results in synthesis of ATP by dephosphorylating IP₆ (Wundenberg *et al.* 2014).

In *S. cerevisiae*, the IP₇ kinase Vip1 synthesizes IP₈ [1,5(PP)₂-I(2,3,4,6)P₄] by adding a phosphate at position 1

on 5-IP₇ (figure 2) (Lin *et al.* 2009; Mulugu *et al.* 2007; Wang *et al.* 2012). In mammals there are two isoforms of Vip1, also known as PPIP5Ks, that synthesize IP₈ from 5-IP₇ (Choi *et al.* 2007; Fridy *et al.* 2007; Tsui and York 2010; Wang *et al.* 2012). Vip1 can also function as an IP₆ kinase and synthesize 1PP-I(2,3,4,5,6)P₅ (1-IP₇) from IP₆, which can then be converted to IP₈ by the action of Kcs1 (figure 2) (Lin *et al.* 2009; Mulugu *et al.* 2007; Tsui and York 2010; Wang *et al.* 2012). Vip1 also possesses a C-terminal histidine acid phosphatase domain (Gokhale *et al.* 2011; Mulugu *et al.* 2007). In Asp1, the Vip1 homologue in *Schizosaccharomyces pombe*, the phosphatase activity of this domain has been shown to reduce the synthesis of 1-IP₇ from IP₆, suggesting that the N-terminal kinase activity of Vip1 may be autoregulated by the C-terminal domain (Pohlmann *et al.* 2014). Recent structural analysis has revealed that this enzyme possesses a unique substrate binding site on its surface which serves to capture the substrate from the bulk phase and direct it towards the catalytic site (Wang *et al.* 2014b). Vip1 paralogs have also recently been identified in Arabidopsis (Desai *et al.* 2014; Laha *et al.* 2015), and shown to be primarily responsible for the synthesis of IP₈ from IP₇. It was shown that an enzyme responsible for the synthesis of IP₇ from IP₆ exists in plants, but is likely to be distinct from mammalian and yeast IP6Ks (Laha *et al.* 2015).

In budding yeast, the deletion of Kcs1 leads to undetectable levels of both IP₇ and IP₈, whereas deletion of Vip1 causes an increase in 5-IP₇ levels (Onnebo and Saiardi 2009). This observation suggests that in yeast, the predominant pathway for IP₈ synthesis from IP₆ is via 5-IP₇, and that 5-IP₇ is more abundant compared with 1-IP₇. In yeast and in mammals there are other minor inositol pyrophosphates, 5PP-IP₄, 1PP-IP₄ and 1,5(PP)₂-IP₃, synthesized from IP₅ (figure 2) (Draskovic *et al.* 2008; Wundenberg and Mayr 2012). In yeast, these minor inositol pyrophosphates are only detectable in the absence of Ipk1, the IP₅ kinase which synthesizes IP₆ (Saiardi *et al.* 2002). IP₆ is the preferred substrate over IP₅ for the synthesis of inositol pyrophosphates due to its high physiological concentration and higher affinity of the IP6Ks for IP₆ (Wundenberg and Mayr 2012). All mammalian IP6Ks can add a γ phosphate to 5-IP₇ to make 5PPP-IP₅, a triphospho- group containing inositol phosphate (Draskovic *et al.* 2008), whose *in vivo* occurrence has not yet been unequivocally demonstrated.

Inositol pyrophosphates are hydrolysed by the enzyme DIPP (diphosphoinositol polyphosphate phosphohydrolase), which exists as five isoforms in mammals, and a single isoform called Ddp1 (diadenosine and diphosphoinositol phosphohydrolase) in yeast (figure 2) (Caffrey *et al.* 2000; Kilari *et al.* 2013; Safrany *et al.* 1998; Safrany *et al.* 1999). DIPPs hydrolyse diphosphate groups on IP₇ and IP₈ to form IP₆, and on PP-IP₄ and (PP)₂-IP₃ to form IP₅ (figure 2).




Figure 2. Pathway of synthesis of inositol pyrophosphates. Synthesis of inositol pyrophosphates, starting with the generation of I(1,4,5)P₃ from PI(4,5)P₂. The pathway that occurs in both yeast and mammals is depicted in black arrows and the pathway that is exclusive to mammals is shown in blue arrows. Yeast enzymes are represented in green; mammalian enzymes are represented in blue; the undetermined inositol pyrophosphate structure is indicated with a question mark.

These hydrolases prefer 1-IP₇ over 5-IP₇ as a substrate (Kilari *et al.* 2013; Lonetti *et al.* 2011), which could contribute to the presence of higher amounts of 5-IP₇ compared to 1-IP₇ in cells.

The levels of inositol pyrophosphates are tightly regulated as a result of constant synthesis by IP₆ and IP₇ kinases and hydrolysis by DIPPs. Early work by the Shears' laboratory indicated a high turnover rate for these molecules, estimating that 50% of the IP₆ pool and 20% of the IP₅ pool are converted into inositol pyrophosphate derivatives every hour in mammalian cells (Menniti *et al.* 1993), and that the IP₇ pool can turn over ten times every 40 min (Glennon and Shears 1993). In yeast, mammals and plants, the steady state levels of the major inositol pyrophosphates, IP₇ and IP₈, have been found to be very low, with 5-IP₇, the most abundant inositol pyrophosphate, occurring at only 1-5% of the level of its precursor, IP₆ (Laha *et al.* 2015; Onnebo and Saiardi 2009; Wundenberg and Mayr 2012). Most of these studies have relied on HPLC based separation and

measurement of inositol polyphosphates (Azevedo and Saiardi 2006). A new method developed by the Saiardi laboratory, which involves pull down of inositol phosphates with titanium oxide beads and analysis by PAGE, suggests that IP₇ levels may be higher in some cell lines, reaching approximately 20% of IP₆ levels in HCT116 cells (Wilson *et al.* 2015). The estimated physiological concentration of IP₇ ranges from 0.5-5 μM, most of which is 5-IP₇ in yeast and mammals (Albert *et al.* 1997; Barker *et al.* 2004; Illies *et al.* 2007; Ingram *et al.* 2003; Lin *et al.* 2009; Onnebo and Saiardi 2009; Wundenberg and Mayr 2012), whereas 1-IP₇ contributes minor levels (Wundenberg and Mayr 2012). Biological levels of IP₈ can vary significantly, from being undetectable in some cells, to up to 10-20% of IP₇ levels in others, (Choi *et al.* 2008; Choi *et al.* 2005; Glennon and Shears 1993; Onnebo and Saiardi 2009; Shears *et al.* 2013; Wilson *et al.* 2015; Wundenberg and Mayr 2012). In contrast to other organisms, slime moulds have high amounts of inositol pyrophosphates, with a recent estimate based on

PAGE analysis showing steady state levels of 60 μM IP_7 and 180 μM IP_8 in *Dictyostelium discoideum* (Pisani *et al.* 2014).

3. Signalling and metabolic functions of inositol pyrophosphates

The low levels of cellular inositol pyrophosphates are similar to steady state levels of IP_3 , which is considered a classical second messenger (Streb *et al.* 1983), and so it is believed that like IP_3 , inositol pyrophosphates can participate in cell signalling. However, unlike IP_3 , levels of inositol pyrophosphates have not been shown to respond dramatically to different external stimuli. Instead it has been seen that cellular ATP levels govern inositol pyrophosphates (see below). Nevertheless, several laboratories have conducted over-expression, knockdown and knockout based analyses of the inositol pyrophosphate synthesizing enzymes, to assign a wide variety of cell and organism level functions to these molecules. At the molecular level however, it is believed that inositol pyrophosphates can act by two mechanisms:

- (A) *Binding*: Inositol phosphates and inositol pyrophosphates are stereospecific in nature. They can bind to specific domains on individual proteins and allosterically regulate protein function. 1- IP_7 has been shown to interact with a cyclin-dependent kinase inhibitor in budding yeast to regulate phosphate metabolism (Lee *et al.* 2008). IP_7 synthesized by mammalian IP6K2 can bind and activate the protein kinase CK2, to trigger a signalling pathway promoting apoptosis (Rao *et al.* 2014a). Several studies have shown that 5- IP_7 can compete with the lipid inositide $\text{PI}(3,4,5)\text{P}_3$ to specifically bind pleckstrin homology (PH) domains and inhibit downstream PIP_3 -PH-domain interaction dependent signalling (Chakraborty *et al.* 2010; Luo *et al.* 2003; Prasad *et al.* 2011; Rao *et al.* 2014a; Wu *et al.* 2013). Interestingly, different PH domains show stronger binding to IP_7 compared with IP_6 , although the degree of difference has been shown to vary (Chakraborty *et al.* 2010; Gokhale *et al.* 2013; Luo *et al.* 2003). This appears counterintuitive, given that IP_4 is considered a mimic for the head-group of $\text{PI}(3,4,5)\text{P}_3$, and the molecular underpinnings for this specificity are yet to be determined. Some PH domains tested in a recent study show a much higher affinity for IP_6 and 5- IP_7 compared with 1- IP_7 and IP_8 (Gokhale *et al.* 2013), underlining the stereospecific nature of protein binding as a mechanism for inositol pyrophosphate function.
- (B) *Pyrophosphorylation*: Pyro is the Greek word for fire or heat, and as suggested by their name, inositol pyrophosphates, are high energy molecules that release energy upon hydrolysis of the pyrophosphate bond.

Based on bond energy calculations, the energy of hydrolysis of C-O-P on the inositol ring is 3-4 kcal/mol whereas the bond energy of P-O-P in IP_7 is 6.6 kcal/mol, which is higher than the P-O-P bond in ADP (6.4 kcal/mol) (Stephens *et al.* 1993; Wundenberg and Mayr 2012). Phosphoanhydride bonds in inositol pyrophosphates are more susceptible to hydrolysis due to the steric interference generated by the surrounding negatively charged phosphate groups, and therefore the energy of their hydrolysis might be higher than the calculated energies (Hand and Honek 2007; Laussmann *et al.* 1996). Inositol pyrophosphates can therefore transfer the β phosphate of the P-O-P bond on the inositol ring to pre-phosphorylated serine residues on proteins, in presence of divalent cations like Mg^{2+} as a co-factor (Bhandari *et al.* 2007). Mass spectrometry analysis of IP_7 substrate proteins has revealed that the pyrophosphorylatable serine residues are present in acidic motifs and are potential substrates for casein kinase 2 (Bhandari *et al.* 2007; Saiardi *et al.* 2004). Thus, inositol pyrophosphates donate their β phosphate to prephosphorylated serine residues and bring about protein pyrophosphorylation (Bhandari *et al.* 2007). Unlike protein binding, which is specific to either 1- or 5- IP_7 (Gokhale *et al.* 2013; Lee *et al.* 2008), serine pyrophosphorylation can be brought about by all inositol pyrophosphates (Bhandari *et al.* 2007). However, until we gain a deeper understanding of the phosphotransfer process from inositol pyrophosphates to phosphoserine, we cannot rule out the possibility of stereoselectivity in the inositol pyrophosphate donor depending on the sequence context of the acceptor phosphoserine. The pyrophosphates on serine residues in proteins are acid labile but they show strong resistance to protein phosphatases (Bhandari *et al.* 2007). Longer incubations of synthetic pyrophosphopeptides with alkaline phosphatases can remove the β phosphate group on pyrophosphoserine containing peptides (Yates and Fiedler 2015), suggesting that protein pyrophosphorylation may be a reversible process participating in many cellular signalling pathways.

Inositol pyrophosphates and the enzymes responsible for their synthesis participate in many physiological pathways from yeast to mammals. Given below is a short summary of the role played by inositol pyrophosphates in each physiological function described for these molecules so far (figure 3).

Growth and stress response: *kcs1* Δ yeast that have decreased levels of IP_7 and IP_8 display slow growth at 30°C, temperature sensitivity at 37°C and increased cell volume, suggesting that inositol pyrophosphates are essential for normal cell growth in yeast (Dubois *et al.* 2002).




Figure 3. Diagrammatic representation of the cellular functions of inositol pyrophosphates. The inositol pyrophosphate in the centre of a eukaryotic cell represents 5-IP₇, 1-IP₇ or IP₈. Red lines depict negative regulation and green arrows represent positive regulation of signalling or metabolic pathways by inositol pyrophosphates. ATP positively influences the intracellular levels of inositol pyrophosphates.

Resistance to salt stress and cell wall integrity also require IP₇ (Dubois *et al.* 2002). In mammalian cells, IP₈ levels rise sharply in response to hyperosmotic or thermal stresses (Choi *et al.* 2005; Pesesse *et al.* 2004), and PIP5K1 is activated in response to a hyperosmotic challenge (Choi *et al.* 2007). Treatment of budding yeast with hydrogen peroxide leads to a reduction in levels of IP₇ and IP₈ via oxidation of a cysteine residue in Kcs1 and direct inhibition of its enzyme activity (Onnebo and Saiardi 2009). Conversely, *kcs1Δ* and *vip1Δ* yeast, which lack IP₈, show resistance to cell death caused by treatment with hydrogen peroxide via increased activation of the Rad53 pathway (Onnebo and Saiardi 2009).

DNA repair: The absence of Kcs1 leads to a defect in DNA recombination, suggesting that Kcs1 products, either 5-IP₇ or 5PP-IP₄, play a role in the regulation of DNA recombination (Huang and Symington 1995; Luo *et al.* 2002). In mammalian

cells the absence of IP6K1 leads to a defect in homologous recombination repair (Jadav *et al.* 2013). Yeast Tel1, a protein that belongs to the phosphoinositide-3-kinase related protein kinase (PIKK) family, is involved in telomere length maintenance, and the action of this kinase is negatively correlated with the levels of PP-IP₄ (Resnick *et al.* 2005; York *et al.* 2005). *kcs1Δ* yeast show reduced survival compared with wild type cells in response to treatment with the DNA double strand break inducer phleomycin (Onnebo and Saiardi 2009). In response to UV stress, mammalian IP6K1 synthesizes IP₇ that further activates the E3 ubiquitin ligase CRL4, which leads to protein degradation, thereby regulating nucleotide excision DNA repair and apoptosis (Rao *et al.* 2014b).

Vesicular trafficking: Yeast that lack inositol pyrophosphates contain abnormally small vesicles and small fragmented vacuoles, and are impaired in endocytic membrane trafficking (Dubois *et al.* 2002; Saiardi *et al.* 2000a; Saiardi *et al.* 2002).

IP₇ has been shown to bind a coatamer protein involved in intercisternal Golgi vesicle transport (Ali *et al.* 1995; Fleischer *et al.* 1994) and the clathrin assembly protein AP180 (Ye *et al.* 1995), and inhibit the functions of these proteins, but a subsequent review pointed out that these assays were conducted under inappropriate salt conditions (Shears 2001). *Ip6k1* knockout mice display reduced plasma insulin levels (Bhandari *et al.* 2008) whereas overexpression of IP6K1 in pancreatic β cells increases the exocytosis of insulin (Illies *et al.* 2007). In mammalian cells, pyrophosphorylation of AP3 β 1 (a subunit of a clathrin associated adaptor protein complex) impairs its interaction with Kif3A (a kinesin motor protein) thereby inhibiting the release of HIV-1 like viral particles (Azevedo *et al.* 2009).

Cell cycle and cell death: In the yeast cell cycle, progression through S phase after release from pheromone induced cell cycle arrest requires IP₇ (Banfic *et al.* 2013). In mammalian cells, IP₇ levels fluctuate during different phases of the cell cycle, but the functional significance of this is unknown (Barker *et al.* 2004). Overexpression of mammalian IP6K2 leads to increased susceptibility to cell death by apoptosis (Morrison *et al.* 2002; Morrison *et al.* 2001; Nagata *et al.* 2005), and binding of Hsp90 to IP6K2 blocks this activity (Chakraborty *et al.* 2008). IP6K2 knockout mice show increased susceptibility to tumourigenesis as a consequence of reduced apoptosis (Morrison *et al.* 2009). Deletion of IP6K2 in mammalian cells impairs p53-mediated apoptosis (Koldobskiy *et al.* 2010) and binding of 5-IP₇ to CK2 enhances p53-mediated cell death (Rao *et al.* 2014a).

Akt signalling: IP₇ acts as a physiological inhibitor of the Akt signalling cascade by binding to the PH domain of Akt, preventing its interaction with PI(3,4,5)P₃ and its subsequent phosphorylation and activation by PDK1. IP₇ therefore reduces Akt membrane translocation and insulin-stimulated glucose uptake (Chakraborty *et al.* 2010). Thus, deletion of *Ip6k1* in mice results in increased insulin sensitivity and resistance to weight gain when fed a high-fat diet (Chakraborty *et al.* 2010). Inositol pyrophosphates regulate aging of bone marrow derived mesenchymal stem cells, with older cells showing more IP₇ levels and reduced Akt signalling compared with young cells (Zhang *et al.* 2014). In human neutrophils, 5-IP₇ inhibits Akt-PI(3,4,5)P₃ interaction mediated functions such as superoxide production and phagocytosis (Prasad *et al.* 2011). IP₇ has also been shown to bind other PH domains. IP₇ binding to PH domains modulates cyclic AMP induced aggregation in *D. discoideum*, and amoebae lacking IP6K show rapid aggregation and increased cyclic AMP sensitivity (Luo *et al.* 2003). PH domain binding appears to be isomer specific, with the PH domains of Akt, SIN1 and GRP1 showing approximately 30 fold higher affinity for 5-IP₇ compared with 1-IP₇ or IP₈ (Gokhale *et al.* 2013).

Phosphate metabolism: In yeast, 1-IP₇, the product of Vip1, binds to Pho80-Pho85-Pho81, a cyclin - cyclin dependent kinase (CDK) – CDK inhibitor complex, and inhibits its kinase activity under phosphate starved conditions to enable Pho4-dependent transcription of phosphate metabolism genes Pho84 (high affinity phosphate uptake transporter) and Pho5 (acid phosphatase involved in P_i mobilization) (Lee *et al.* 2008). In *vip1 Δ yeast, Pho4 remains inactive during phosphate starvation (Lee *et al.* 2007). Conversely, Kcs1 mutant yeast constitutively express Pho5, and overexpression of Kcs1 leads to suppression of Pho5 expression under low phosphate conditions (Auesukaree *et al.* 2005). There are conflicting reports on the effect phosphate starvation in yeast has on the levels of total IP₇, with one report showing that total IP₇ levels rise upon phosphate starvation (Lee *et al.* 2007) and a contrasting report showing that total IP₇ goes down upon phosphate starvation (Lonetti *et al.* 2011; Saiardi 2012b). Deletion of Kcs1 causes reduced uptake of inorganic phosphate in yeast (Saiardi *et al.* 2004), and in vertebrates, phosphate uptake is increased upon over-expression of IP6K2 (Norbis *et al.* 1997).*

Polyphosphates are long chains of inorganic phosphate moieties linked by phosphodiester bonds, and have a size range of 60-100 units per chain in eukaryotes. Yeast that lack Kcs1 are deprived of polyphosphates whereas yeast lacking Vip1 have normal levels of polyphosphates (Auesukaree *et al.* 2005; Lonetti *et al.* 2011). Adding back active but not inactive mouse IP6K1 restored polyphosphate levels in *kcs1 Δ yeast, suggesting that 5-IP₇ is required to maintain normal levels of polyphosphate in yeast (Lonetti *et al.* 2011). *Ip6k1* knockout mice do not have platelet polyphosphates and show defects in blood clotting (Ghosh *et al.* 2013). Addition of polyphosphates but not IP₇ could rescue clotting in sera derived from *Ip6k1* knockout mice (Ghosh *et al.* 2013). These studies indicate that a metabolic link exists between 5-IP₇ and polyphosphates, which is conserved in yeast and mammals, but the molecular basis of this link is yet to be uncovered.*

Energy homeostasis: The low affinity of inositol hexakisphosphate kinases towards ATP ($K_m \sim 1$ mM) (Saiardi *et al.* 1999; Voglmaier *et al.* 1996; Wundenberg and Mayr 2012), lies in the same range as cellular ATP levels, reflecting the fact that 5-IP₇ levels can be influenced by changes in intracellular ATP concentration (Choi *et al.* 2008; Nagel *et al.* 2010). Yeast lacking 5-IP₇ and mouse embryonic fibroblasts lacking IP6K1 display dysfunctional mitochondria, leading to a reduction in ATP synthesis through the electron transport chain (Szijgyarto *et al.* 2011). In yeast, inositol pyrophosphates regulate the transcription of major glycolytic pathway genes by pyrophosphorylating and reducing the activity of the transcription factor Gcr1. Therefore, the loss of 5-IP₇ in *kcs1 Δ yeast leads to increased*

transcription of glycolytic enzymes, thereby increasing ATP synthesis via glycolysis (Sziygyarto *et al.* 2011). Put together, these observations suggest that inositol pyrophosphates are influenced by cellular ATP levels and act in a feedback mechanism to maintain the levels of ATP by controlling the glycolytic vs mitochondrial metabolic ratio (Sziygyarto *et al.* 2011).

Ribosome biogenesis: Yeast nucleolar proteins Nsr1 and Srp40 are targets of pyrophosphorylation by inositol pyrophosphates (Bhandari *et al.* 2007; Saiardi *et al.* 2004). These proteins are involved in the localisation of box C/D snoRNA, which in turn are required for ribose methylation in rRNA (Verheggen *et al.* 2001). It was shown that deletion of Kcs1 in budding yeast is able to rescue the cold sensitivity of an *rrs1* mutant, which shows a defect in assembly of the 60S ribosome subunit (Horigome *et al.* 2014). *kcs1Δ* yeast grown at 16°C showed reduced levels of polysomes assembled on mRNA compared to 80S monosomes (Horigome *et al.* 2014). A recent study by our group revealed that RNA Pol I, the enzyme responsible for synthesis of rRNA is pyrophosphorylated by IP₇, and that rRNA synthesis and ribosome levels are reduced in the absence of inositol pyrophosphates (Thota *et al.* 2015). This observation suggested that RNA Pol I pyrophosphorylation by 5-IP₇ is required for its activity. Cellular ATP levels determine not only the synthesis of IP₇ but also the synthesis of ribosomes, as this process accounts for 80% of a cell's ATP consumption. We speculate that IP₇ acts as a mediator molecule, signalling the availability of ATP to RNA Pol I to pursue rRNA synthesis.

Chromatin remodelling: In yeast, inositol pyrophosphates function parallel to the TORC pathway to regulate the class I histone deacetylase, Rpd3L, thus regulating chromatin remodelling in response to stress or starvation signals (Worley *et al.* 2013). In mammals, IP6K1 is associated with chromatin and binds the histone demethylase JMJD2C (Burton *et al.* 2013). IP₇ synthesised by IP6K1 indirectly inhibits the activity of JMJD2C, leading to specific alterations in histone methylation and acetylation in cells lacking IP6K1 (Burton *et al.* 2013).

Other functions of inositol pyrophosphates: In mammals, the antiviral immune response pathway is positively regulated by 1-IP₇ which enhances the production of type 1 interferon by increasing the phosphorylation and activation of the transcription factor IRF3. A non-hydrolysable analogue of IP₇ was not able to recapitulate this effect, suggesting that IP₇ may act by pyrophosphorylation of IRF3 (Pulloor *et al.* 2014). Yeast that lack Kcs1 show decreased expression of Ino1, the inositol-3-P synthase which catalyses the rate limiting step in inositol synthesis from glucose-6-P. This suggests that inositol pyrophosphates regulate their own metabolism by regulating the levels of inositol (Ye *et al.* 2013). Yeast and mammals with

reduced IP₇ levels display defects in autophagy (Nagata *et al.* 2010; Taylor *et al.* 2012). *Ip6k1* knockout male mice are sterile and display a severe reduction in mature spermatozoa in the epididymis, suggesting that this enzyme or its product 5-IP₇ is essential for spermatogenesis (Bhandari *et al.* 2008). IP₇ synthesised by mammalian IP6K2 sequesters the protein kinase LKB1 leading to enhanced cell migration and tumour metastasis (Rao *et al.* 2015).

4. A perspective on the future of inositol pyrophosphate research

Inositol pyrophosphates display pleiotropic effects in cells by regulating various biological processes as a consequence of binding to or pyrophosphorylating many different proteins. Since the discovery of inositol pyrophosphates in 1993, research has been focused mostly on their physiological implications rather than the regulation of their synthesis. The synthesis of inositol pyrophosphates depends on availability of ATP (Nagel *et al.* 2010; figure 3), and it is therefore speculated that IP₇ can act as a 'metabolic messenger' or 'energy biosensor' to co-ordinate between energy flux and signalling pathways (Shears 2009, 2015; Wilson *et al.* 2013). For example, in yeast, absence of IP₇ results in a reduction in ribosome synthesis, a process that consumes 80% of the cell's energy (Thota *et al.* 2015). Inositol pyrophosphates also regulate the HDAC Rpd3L, thereby affecting gene expression in phosphate starvation, glycolysis, ribosome biogenesis and environmental stress response pathways (Worley *et al.* 2013). Inositol pyrophosphate levels influence the levels of polyphosphate (Auesukaree *et al.* 2005; Ghosh *et al.* 2013; Lonetti *et al.* 2011), a macromolecule which also depends on ATP for its synthesis. Progression through the cell cycle from G1 to S phase is accompanied by a gradual increase in the levels of inositol pyrophosphates (Banfic *et al.* 2013), and it is known that transition through the G1/S checkpoint is dependent on the energy status of the cell (Finkel and Hwang 2009). Thus, inositol pyrophosphates could act on many cellular pathways simply by transducing ATP levels. On the other hand, it is also likely that the enzyme activity and localisation of inositol pyrophosphate kinases and hydrolases is regulated by different signals to influence inositol pyrophosphate levels and sub-cellular localisation (Shears 2015; Thomas and Potter 2014). The low cellular concentration of IP₇ and IP₈ suggests that their synthesis should occur in close proximity to the proteins that will be pyrophosphorylated or provide docking sites for their binding. This would ensue only when inositol pyrophosphate kinases are localised to the target proteins and this localisation may in turn depend on upstream regulators. Therefore, future studies should focus

on determining the regulation of expression, activity, sub-cellular localisation and interacting partners of the enzymes that synthesize and degrade inositol pyrophosphates, and link this information to the protein targets through which inositol pyrophosphates influence individual pathways governing cell physiology.

Acknowledgements

We thank Manasa Chanduri for invaluable feedback during the writing of this review. We thank Shubhra Ganguli and Pallavi Chinnu Varghese for artwork. The Bhandari Lab is supported by the Wellcome Trust/Department of Biotechnology India Alliance (WT/DBT IA; 500020/Z/09/Z) and Centre for DNA Fingerprinting and Diagnostics core funds. SGT is a recipient of a research fellowship from the Department of Biotechnology toward the pursuit of a Ph.D. degree of the Manipal University. RB is supported by a senior fellowship from the WT/DBT IA.

References

- Agranoff BW 1986 Phosphorylated derivatives of myo-inositol. *Fed. Proc.* **45** 2629–2633
- Agranoff BW 2009 Turtles all the way: reflections on myo-Inositol. *J. Biol. Chem.* **284** 21121–21126
- Albert C, Safrany ST, Bembenek ME, Reddy KM, Reddy K, Falck J, Brocker M, Shears SB, *et al.* 1997 Biological variability in the structures of diphosphoinositol polyphosphates in *Dictyostelium discoideum* and mammalian cells. *Biochem. J.* **327** 553–560
- Ali N, Duden R, Bembenek ME and Shears SB 1995 The interaction of coatamer with inositol polyphosphates is conserved in *Saccharomyces cerevisiae*. *Biochem. J.* **310** 279–284
- Auesukaree C, Tochio H, Shirakawa M, Kaneko Y and Harashima S 2005 Plc1p, Arg82p, and Kcs1p, enzymes involved in inositol pyrophosphate synthesis, are essential for phosphate regulation and polyphosphate accumulation in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **280** 25127–25133
- Azevedo C and Saiardi A 2006 Extraction and analysis of soluble inositol polyphosphates from yeast. *Nat. Protoc.* **1** 2416–2422
- Azevedo C, Burton A, Ruiz-Mateos E, Marsh M and Saiardi A 2009 Inositol pyrophosphate mediated pyrophosphorylation of AP3B1 regulates HIV-1 Gag release. *Proc. Natl. Acad. Sci. USA* **106** 21161–21166
- Azevedo C, Sziogyarto Z and Saiardi A 2011 The signaling role of inositol hexakisphosphate kinases (IP6Ks). *Adv. Enzym. Regul.* **51** 74–82
- Banfic H, Bedalov A, York JD and Visnjic D 2013 Inositol pyrophosphates modulate S phase progression after pheromone-induced arrest in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **288** 1717–1725
- Barker CJ and Berggren PO 2013 New horizons in cellular regulation by inositol polyphosphates: insights from the pancreatic beta-cell. *Pharmacol. Rev.* **65** 641–669
- Barker CJ, Wright J, Hughes PJ, Kirk CJ and Michell RH 2004 Complex changes in cellular inositol phosphate complement accompany transit through the cell cycle. *Biochem. J.* **380** 465–473
- Barker CJ, Illies C, Gaboardi GC and Berggren PO 2009 Inositol pyrophosphates: structure, enzymology and function. *Cell. Mol. Life Sci.* **66** 3851–3871
- Bennett M, Onnebo SM, Azevedo C and Saiardi A 2006 Inositol pyrophosphates: metabolism and signaling. *Cell. Mol. Life Sci.* **63** 552–564
- Berridge MJ, Bootman MD and Roderick HL 2003 Calcium signalling: dynamics, homeostasis and remodelling. *Nat. Rev. Mol. Cell Biol.* **4** 517–529
- Bhandari R, Saiardi A, Ahmadibeni Y, Snowman AM, Resnick AC, Kristiansen TZ, Molina H, Pandey A, *et al.* 2007 Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational event. *Proc. Natl. Acad. Sci. USA* **104** 15305–15310
- Bhandari R, Juluri KR, Resnick AC and Snyder SH 2008 Gene deletion of inositol hexakisphosphate kinase 1 reveals inositol pyrophosphate regulation of insulin secretion, growth, and spermiogenesis. *Proc. Natl. Acad. Sci. USA* **105** 2349–2353
- Burton A, Hu X and Saiardi A 2009 Are inositol pyrophosphates signalling molecules? *J. Cell Physiol.* **220** 8–15
- Burton A, Azevedo C, Andreassi C, Riccio A and Saiardi A 2013 Inositol pyrophosphates regulate JMJD2C-dependent histone demethylation. *Proc. Natl. Acad. Sci. USA* **110** 18970–18975
- Caffrey JJ, Safrany ST, Yang X and Shears SB 2000 Discovery of molecular and catalytic diversity among human diphosphoinositol-polyphosphate phosphohydrolases. An expanding Nudt family. *J. Biol. Chem.* **275** 12730–12736
- Chakraborty A, Koldobskiy MA, Sixt KM, Juluri KR, Mustafa AK, Snowman AM, van Rossum DB, Patterson RL, *et al.* 2008 HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. *Proc. Natl. Acad. Sci. USA* **105** 1134–1139
- Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, Juluri KR, Maag D, Kim S, *et al.* 2010 Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. *Cell* **143** 897–910
- Chakraborty A, Kim S and Snyder SH 2011 Inositol pyrophosphates as mammalian cell signals. *Sci. Signal.* **4** 1–11
- Choi K, Mollapour E and Shears SB 2005 Signal transduction during environmental stress: InsP(8) operates within highly restricted contexts. *Cell Signal.* **17** 1533–1541
- Choi JH, Williams J, Cho J, Falck JR and Shears SB 2007 Purification, sequencing, and molecular identification of a mammalian PP-InsP5 kinase that is activated when cells are exposed to hyperosmotic stress. *J. Biol. Chem.* **282** 30763–30775
- Choi K, Mollapour E, Choi JH and Shears SB 2008 Cellular energetic status supervises the synthesis of bis-diphosphoinositol tetrakisphosphate independently of AMP-activated protein kinase. *Mol. Pharmacol.* **74** 527–536
- Desai M, Rangarajan P, Donahue JL, Williams SP, Land ES, Mandal MK, Phillippy BQ, Perera IY, *et al.* 2014 Two inositol hexakisphosphate kinases drive inositol pyrophosphate synthesis in plants. *Plant J.* **80** 642–653
- Dewaste V, Pouillon V, Moreau C, Shears S, Takazawa K and Erneux C 2000 Cloning and expression of a cDNA encoding

- human inositol 1,4,5-trisphosphate 3-kinase C. *Biochem. J.* **352** 343–351
- Draskovic P, Saiardi A, Bhandari R, Burton A, Ilc G, Kovacevic M, Snyder SH and Podobnik M 2008 Inositol hexakisphosphate kinase products contain diphosphate and triphosphate groups. *Chem. Biol.* **15** 274–286
- Dubois E, Scherens B, Vierendeels F, Ho MM, Messenguy F and Shears SB 2002 In *Saccharomyces cerevisiae*, the inositol polyphosphate kinase activity of Kcs1p is required for resistance to salt stress, cell wall integrity, and vacuolar morphogenesis. *J. Biol. Chem.* **277** 23755–23763
- Finkel T and Hwang PM 2009 The Krebs cycle meets the cell cycle: mitochondria and the G1-S transition. *Proc. Natl. Acad. Sci. USA.* **106** 11825–11826
- Fleischer B, Xie J, Mayrleitner M, Shears SB, Palmer DJ and Fleischer S 1994 Golgi coatomer binds, and forms K(+)-selective channels gated by, inositol polyphosphates. *J. Biol. Chem.* **269** 17826–17832
- Flick JS and Thorner J 1993 Genetic and biochemical characterization of a phosphatidylinositol-specific phospholipase C in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **13** 5861–5876
- Fridy PC, Otto JC, Dollins DE and York JD 2007 Cloning and characterization of two human VIP1-like inositol hexakisphosphate and diphosphoinositol pentakisphosphate kinases. *J. Biol. Chem.* **282** 30754–30762
- Ghosh S, Shukla D, Suman K, Lakshmi BJ, Manorama R, Kumar S and Bhandari R 2013 Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. *Blood* **122** 1478–1486
- Glennon MC and Shears SB 1993 Turnover of inositol pentakisphosphates, inositol hexakisphosphate and diphosphoinositol polyphosphates in primary cultured hepatocytes. *Biochem. J.* **293** 583–590
- Gokhale NA, Zaremba A, and Shears SB 2011 Receptor-dependent compartmentalization of PPIP5K1, a kinase with a cryptic polyphosphoinositide binding domain. *Biochem. J.* **434** 415–426
- Gokhale NA, Zaremba A, Janoshazi AK, Weaver JD and Shears SB 2013 PPIP5K1 modulates ligand competition between diphosphoinositol polyphosphates and PtdIns(3,4,5)P3 for polyphosphoinositide-binding domains. *Biochem. J.* **453** 413–426
- Gonzalez B, Schell MJ, Letcher AJ, Veprintsev DB, Irvine RF and Williams RL 2004 Structure of a human inositol 1,4,5-trisphosphate 3-kinase: substrate binding reveals why it is not a phosphoinositide 3-kinase. *Mol. Cell* **15** 689–701
- Hand CE and Honek JF 2007 Phosphate transfer from inositol pyrophosphates InsP(5)PP and InsP(4)(PP)(2): A semi-empirical investigation. *Bioorg. Med. Chem. Lett.* **17** 183–188
- Hansen CA, Johanson RA, Williamson MT and Williamson JR 1987 Purification and characterization of two types of soluble inositol phosphate 5-phosphomonoesterases from rat brain. *J. Biol. Chem.* **262** 17319–17326
- Holmes W and Jogl G 2006 Crystal structure of inositol phosphate multikinase 2 and implications for substrate specificity. *J. Biol. Chem.* **281** 38109–38116
- Horigome C, Ikeda R, Okada T, Takenami K and Mizuta K 2014 Genetic interaction between ribosome biogenesis and inositol polyphosphate metabolism in *Saccharomyces cerevisiae*. *Biosci. Biotechnol. Biochem.* **73** 443–446
- Huang KN and Symington LS 1995 Suppressors of a *Saccharomyces cerevisiae* pkc1 mutation identify alleles of the phosphatase gene PTC1 and of a novel gene encoding a putative basic leucine zipper protein. *Genetics* **141** 1275–1285
- Illies C, Gromada J, Fiume R, Leibiger B, Yu J, Juhl K, Yang S-N, Barma DK, et al. 2007 Requirement of inositol pyrophosphates for full exocytotic capacity in pancreatic cells. *Science* **318** 1299–1302
- Ingram SW, Safrany ST and Barnes LD 2003 Disruption and overexpression of the *Schizosaccharomyces pombe* apsl1 gene, and effects on growth rate, morphology and intracellular diadenosine 5',5'''-P1, P5-pentaphosphate and diphosphoinositol polyphosphate concentrations. *Biochem. J.* **369** 519–528
- Irvine RF and Schell MJ 2001 Back in the water: the return of the inositol phosphates. *Nat. Rev. Mol. Cell Biol.* **2** 327–338
- Jadav RS, Chanduri MV, Sengupta S and Bhandari R 2013 Inositol pyrophosphate synthesis by inositol hexakisphosphate kinase 1 is required for homologous recombination repair. *J. Biol. Chem.* **288** 3312–3321
- Kilari RS, Weaver JD, Shears SB and Safrany ST 2013 Understanding inositol pyrophosphate metabolism and function: kinetic characterization of the DIPP. *FEBS Lett.* **587** 3464–3470
- Koldobskiy MA and Snyder SH 2014 Inositol pyrophosphates in cell death and life. *Cell Cycle* **10** 568–570
- Koldobskiy MA, Chakraborty A, Werner JK Jr, Snowman AM, Juluri KR, Vandiver MS, Kim S, Heletz S, et al. 2010 p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. *Proc. Natl. Acad. Sci. USA* **107** 20947–20951
- Laha D, Johnen P, Azevedo C, Dynowski M, Weiss M, Capolicchio S, Mao H, Iven T, et al. 2015. VIH2 regulates the synthesis of inositol pyrophosphate InsP8 and jasmonate-dependent defenses in *Arabidopsis*. *Plant Cell* **27** 1082–1097
- Laussmann T, Eujen R, Weissshuhn CM, Thiel U and Vogel G 1996 Structures of diphospho-myo-inositol pentakisphosphate and bisdiphospho-myo-inositol tetrakisphosphate from *Dictyostelium* resolved by NMR analysis. *Biochem. J.* **315** 715–720
- Lee YS, Mulugu S, York JD and O'Shea EK 2007 Regulation of a cyclin-CDK-CDK inhibitor complex by inositol pyrophosphates. *Science* **316** 109–112
- Lee YS, Huang K, Quioco FA and O'Shea EK 2008 Molecular basis of cyclin-CDK-CKI regulation by reversible binding of an inositol pyrophosphate. *Nat. Chem. Biol.* **4** 25–32
- Lin H, Fridy PC, Ribeiro AA, Choi JH, Barma DK, Vogel G, Falck JR, Shears SB, et al. 2009 Structural analysis and detection of biological inositol pyrophosphates reveal that the family of VIP/diphosphoinositol pentakisphosphate kinases are 1/3-kinases. *J. Biol. Chem.* **284** 1863–1872
- Lonetti A, Sziogyarto Z, Bosch D, Loss O, Azevedo C and Saiardi A 2011 Identification of an evolutionarily conserved family of inorganic polyphosphate endopolyphosphatases. *J. Biol. Chem.* **286** 31966–31974
- Luo HR, Saiardi A, Yu H, Nagata E, Ye K and Snyder SH 2002 Inositol pyrophosphates are required for DNA hyperrecombination in protein kinase c1 mutant yeast. *Biochemistry* **41** 2509–2515
- Luo HR, Huang YE, Chen JC, Saiardi A, Iijima M, Ye K, Huang Y, Nagata E, et al. 2003 Inositol pyrophosphates mediate chemotaxis in *Dictyostelium* via pleckstrin homology domain-PtdIns(3,4,5)P3 interactions. *Cell* **114** 559–572

- Mayr GW, Radenberg T, Thiel U, Vogel G and Stephens LR 1992 Phosphoinositol diphosphates: non-enzymic formation in vitro and occurrence in vivo in the cellular slime mold *Dictyostelium*. *Carbohydr. Res.* **234** 247–262
- Menniti FS, Miller RN, Putney JW Jr and Shears SB 1993 Turnover of inositol polyphosphate pyrophosphates in pancreaticoma cells. *J. Biol. Chem.* **268** 3850–3856
- Miller GJ and Hurley JH 2004 Crystal structure of the catalytic core of inositol 1,4,5-trisphosphate 3-kinase. *Mol. Cell.* **15** 703–711
- Morrison BH, Bauer JA, Kalvakolanu DV and Lindner DJ 2001 Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. *J. Biol. Chem.* **276** 24965–24970
- Morrison BH, Bauer JA, Hu J, Grane RW, Ozdemir AM, Chawla-Sarkar M, Gong B, Almasan A, *et al.* 2002 Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. *Oncogene* **21** 1882–1889
- Morrison BH, Haney R, Lamarre E, Drazba J, Prestwich GD and Lindner DJ 2009 Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma. *Oncogene* **28** 2383–2392
- Mulugu S, Bai W, Fridy PC, Bastidas RJ, Otto JC, Dollins DE, Haystead TA, Ribeiro AA, *et al.* 2007 A conserved family of enzymes that phosphorylate inositol hexakisphosphate. *Science* **316** 106–109
- Nagata E, Luo HR, Saiardi A, Bae BI, Suzuki N and Snyder SH 2005 Inositol hexakisphosphate kinase-2, a physiologic mediator of cell death. *J. Biol. Chem.* **280** 1634–1640
- Nagata E, Saiardi A, Tsukamoto H, Satoh T, Itoh Y, Itoh J, Shibata M, Takizawa S, *et al.* 2010 Inositol hexakisphosphate kinases promote autophagy. *Int. J. Biochem. Cell Biol.* **42** 2065–2071
- Nagel A, Barker CJ, Berggren PO and Illies C 2010 Diphosphoinositol polyphosphates and energy metabolism: assay for ATP/ADP ratio. *Methods Mol. Biol.* **645** 123–131
- Nomenclature Committee of the International Union of Biochemistry (NC-IUB) 1989a Numbering of atoms in myo-inositol. Recommendations 1988. *Eur. J. Biochem.* **180** 485–486
- Nomenclature Committee of the International Union of Biochemistry 1989b. Numbering of atoms in myo-inositol. Recommendations 1988. *Biochem. J.* **258** 1–2
- Norbis F, Boll M, Stange G, Markovich D, Verrey F, Biber J and Murer H 1997 Identification of a cDNA/protein leading to an increased Pi-uptake in *Xenopus laevis* oocytes. *J. Membr. Biol.* **156** 19–24
- Odom AR, Stahlberg A, Wente SR and York JD 2000 A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. *Science* **287** 2026–2029
- Onnebo SM and Saiardi A 2009 Inositol pyrophosphates modulate hydrogen peroxide signalling. *Biochem. J.* **423** 109–118
- Pesesse X, Choi K, Zhang T and Shears SB 2004 Signaling by higher inositol polyphosphates. Synthesis of bisdiphosphoinositol tetrakisphosphate ("InsP8") is selectively activated by hyperosmotic stress. *J. Biol. Chem.* **279** 43378–43381
- Pisani F, Livermore T, Rose G, Chubb JR, Gaspari M and Saiardi A 2014 Analysis of *Dictyostelium discoideum* inositol pyrophosphate metabolism by gel electrophoresis. *PLoS One* **9** e85533
- Pohlmann J, Risse C, Seidel C, Pohlmann T, Jakopec V, Walla E, Ramrath P, Takeshita N, *et al.* 2014 The Vip1 inositol polyphosphate kinase family regulates polarized growth and modulates the microtubule cytoskeleton in fungi. *PLoS Genet.* **10** e1004586
- Prasad A, Jia Y, Chakraborty A, Li Y, Jain SK, Zhong J, Roy SG, Loison F, *et al.* 2011 Inositol hexakisphosphate kinase 1 regulates neutrophil function in innate immunity by inhibiting phosphatidylinositol-(3,4,5)-trisphosphate signaling. *Nat. Immunol.* **12** 752–760
- Pulloor NK, Nair S, Kostic AD, Bist P, Weaver JD, Riley AM, Tyagi R, Uchil PD, *et al.* 2014 Human genome-wide RNAi screen identifies an essential role for inositol pyrophosphates in Type-I interferon response. *PLoS Pathog.* **10** e1003981
- Rao F, Cha J, Xu J, Xu R, Vandiver MS, Tyagi R, Tokhunts R, Koldobskiy MA, *et al.* 2014a Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2. *Mol. Cell* **54** 119–132
- Rao F, Xu J, Khan AB, Gadalla MM, Cha JY, Xu R, Tyagi R, Dang Y, *et al.* 2014b Inositol hexakisphosphate kinase-1 mediates assembly/disassembly of the CRL4-signalosome complex to regulate DNA repair and cell death. *Proc. Natl. Acad. Sci. USA* **111** 16005–16010
- Rao F, Xu J, Fu C, Cha JY, Gadalla MM, Xu R, Barrow JC and Snyder SH 2015 Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1. *Proc. Natl. Acad. Sci. USA* **112** 1773–1778
- Resnick AC, Snowman AM, Kang BN, Hurt KJ, Snyder SH and Saiardi A 2005 Inositol polyphosphate multikinase is a nuclear PI3-kinase with transcriptional regulatory activity. *Proc. Natl. Acad. Sci. USA* **102** 12783–12788
- Safrany ST, Caffrey JJ, Yang X, Bembenek ME, Moyer MB, Burkhart WA and Shears SB 1998 A novel context for the 'MutT' module, a guardian of cell integrity, in a diphosphoinositol polyphosphate phosphohydrolase. *EMBO J.* **17** 6599–6607
- Safrany ST, Ingram SW, Cartwright JL, Falck JR, McLennan AG, Barnes LD and Shears SB 1999 The diadenosine hexaphosphate hydrolases from *Schizosaccharomyces pombe* and *Saccharomyces cerevisiae* are homologues of the human diphosphoinositol polyphosphate phosphohydrolase. Overlapping substrate specificities in a MutT-type protein. *J. Biol. Chem.* **274** 21735–21740
- Saiardi A 2012a Cell signalling by inositol pyrophosphates. *Subcell. Biochem.* **59** 413–443
- Saiardi A 2012b How inositol pyrophosphates control cellular phosphate homeostasis? *Adv. Biol. Regul.* **52** 351–359
- Saiardi A, Erdjument-Bromage H, Snowman AM, Tempst P and Snyder SH 1999 Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases. *Curr. Biol.* **9** 1323–1326
- Saiardi A, Caffrey JJ, Snyder SH and Shears SB 2000a The inositol hexakisphosphate kinase family. Catalytic flexibility and function in yeast vacuole biogenesis. *J. Biol. Chem.* **275** 24686–24692
- Saiardi A, Caffrey JJ, Snyder SH and Shears SB 2000b Inositol polyphosphate multikinase (ArgRIII) determines nuclear mRNA export in *Saccharomyces cerevisiae*. *FEBS Lett.* **468** 28–32
- Saiardi A, Nagata E, Luo HR, Snowman AM and Snyder SH 2001 Identification and characterization of a novel inositol hexakisphosphate kinase. *J. Biol. Chem.* **276** 39179–39185

- Saiardi A, Sciambi C, McCaffery JM, Wendland B and Snyder SH 2002 Inositol pyrophosphates regulate endocytic trafficking. *Proc. Natl. Acad. Sci. USA* **99** 14206–14211
- Saiardi A, Bhandari R, Resnick AC, Snowman AM and Snyder SH 2004 Phosphorylation of proteins by inositol pyrophosphates. *Science* **306** 2101–2105
- Shears SB 2001 Assessing the omnipotence of inositol hexakisphosphate. *Cell. Signal.* **13** 151–158
- Shears SB 2007 Understanding the biological significance of diphosphoinositol polyphosphates ('inositol pyrophosphates'). *Biochem. Soc. Symp.* **74** 211–221
- Shears SB 2009 Diphosphoinositol polyphosphates: metabolic messengers? *Mol. Pharmacol.* **76** 236–252
- Shears SB 2015 Inositol pyrophosphates: why so many phosphates? *Adv. Biol. Regul.* **57** 203–216
- Shears SB, Gokhale NA, Wang H and Zaremba A 2011 Diphosphoinositol polyphosphates: what are the mechanisms? *Adv. Enzym. Regul.* **51** 13–25
- Shears SB, Weaver JD and Wang H 2013 Structural insight into inositol pyrophosphate turnover. *Adv. Biol. Regul.* **53** 19–27
- Stephens L, Radenberg T, Thiel U, Vogel G, Khoo KH, Dell A, Jackson TR, Hawkins PT, *et al.* 1993 The detection, purification, structural characterization, and metabolism of diphosphoinositol pentakisphosphate(s) and bisdiphosphoinositol tetrakisphosphate(s). *J. Biol. Chem.* **268** 4009–4015
- Streb H, Irvine RF, Berridge MJ and Schulz I 1983 Release of Ca²⁺ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. *Nature* **306** 67–69
- Szjgyarto Z, Garedew A, Azevedo C and Saiardi A 2011 Influence of inositol pyrophosphates on cellular energy dynamics. *Science* **334** 802–805
- Takazawa K, Lemos M, Delvaux A, Lejeune C, Dumont JE and Erneux C 1990 Rat brain inositol 1,4,5-trisphosphate 3-kinase. *Biochem. J.* **268** 213–217
- Takazawa K, Perret J, Dumont JE and Erneux C 1991 Molecular cloning and expression of a human brain inositol 1,4,5-trisphosphate 3-kinase. *Biochem. Biophys. Res. Commun.* **174** 529–535
- Taylor R Jr, Chen PH, Chou CC, Patel J and Jin SV 2012 KCS1 deletion in *Saccharomyces cerevisiae* leads to a defect in translocation of autophagic proteins and reduces autophagosome formation. *Autophagy* **8** 1300–1311
- Thomas MP and Potter BV 2014 The enzymes of human diphosphoinositol polyphosphate metabolism. *FEBS J.* **281** 14–33
- Thota SG, Unnikannan CP, Thampatty SR, Manorama R and Bhandari R 2015 Inositol pyrophosphates regulate RNA polymerase I-mediated rRNA transcription in *Saccharomyces cerevisiae*. *Biochem. J.* **466** 105–114
- Tsui MM and York JD 2010 Roles of inositol phosphates and inositol pyrophosphates in development, cell signaling and nuclear processes. *Adv. Enzym. Regul.* **50** 324–337
- Varnai P and Balla T 2006 Live cell imaging of phosphoinositide dynamics with fluorescent protein domains. *Biochim. Biophys. Acta.* **1761** 957–967
- Verbsky JW, Wilson MP, Kisseleva MV, Majerus PW and Wente SR 2002 The synthesis of inositol hexakisphosphate. Characterization of human inositol 1,3,4,5,6-pentakisphosphate 2-kinase. *J. Biol. Chem.* **277** 31857–31862
- Verbsky JW, Chang SC, Wilson MP, Mochizuki Y and Majerus PW 2005 The pathway for the production of inositol hexakisphosphate in human cells. *J. Biol. Chem.* **280** 1911–1920
- Verheggen C, Mouaikel J, Thiry M, Blanchard JM, Tollervey D, Bordonne R, Lafontaine DL and Bertrand E 2001 Box C/D small nucleolar RNA trafficking involves small nucleolar RNP proteins, nucleolar factors and a novel nuclear domain. *EMBO J.* **20** 5480–5490
- Voglmaier SM, Keen JH, Murphy JE, Ferris CD, Prestwich GD, Snyder SH and Theibert AB 1992 Inositol hexakisphosphate receptor identified as the clathrin assembly protein AP-2. *Biochem. Biophys. Res. Commun.* **187** 158–163
- Voglmaier SM, Bembenek ME, Kaplin AI, Dorman G, Olszewski JD, Prestwich GD and Snyder SH 1996 Purified inositol hexakisphosphate kinase is an ATP synthase: diphosphoinositol pentakisphosphate as a high-energy phosphate donor. *Proc. Natl. Acad. Sci. USA* **93** 4305–4310
- Wang H, Falck JR, Hall TM and Shears SB 2012 Structural basis for an inositol pyrophosphate kinase surmounting phosphate crowding. *Nat. Chem. Biol.* **8** 111–116
- Wang H, DeRose EF, London RE and Shears SB 2014a IP6K structure and the molecular determinants of catalytic specificity in an inositol phosphate kinase family. *Nat. Commun.* **5** 4178
- Wang H, Godage HY, Riley AM, Weaver JD, Shears SB and Potter BV 2014b Synthetic inositol phosphate analogs reveal that PPIP5K2 has a surface-mounted substrate capture site that is a target for drug discovery. *Chem. Biol.* **21** 689–699
- Wilson MP and Majerus PW 1996 Isolation of inositol 1,3,4-trisphosphate 5/6-kinase, cDNA cloning and expression of the recombinant enzyme. *J. Biol. Chem.* **271** 11904–11910
- Wilson MS, Livermore TM and Saiardi A 2013 Inositol pyrophosphates: between signalling and metabolism. *Biochem. J.* **452** 369–379
- Wilson MS, Bulley SJ, Pisani F, Irvine RF and Saiardi A 2015 A novel method for the purification of inositol phosphates from biological samples reveals that no phytate is present in human plasma or urine. *Open Biol.* **5** 150014
- Worley J, Luo X and Capaldi AP 2013 Inositol pyrophosphates regulate cell growth and the environmental stress response by activating the HDAC Rpd3L. *Cell Rep.* **3** 1476–1482
- Wu M, Dul BE, Trevisan AJ and Fiedler D 2013 Synthesis and characterization of non-hydrolysable diphosphoinositol polyphosphate second messengers. *Chem. Sci.* **4** 405–410
- Wundenberg T and Mayr GW 2012 Synthesis and biological actions of diphosphoinositol phosphates (inositol pyrophosphates), regulators of cell homeostasis. *Biol. Chem.* **393** 979–998
- Wundenberg T, Grabinski N, Lin H and Mayr GW 2014 Discovery of InsP6-kinases as InsP6-dephosphorylating enzymes provides a new mechanism of cytosolic InsP6 degradation driven by the cellular ATP/ADP ratio. *Biochem. J.* **462** 173–184
- Yang YR, Follo MY, Cocco L and Suh PG 2013 The physiological roles of primary phospholipase C. *Adv. Biol. Regul.* **53** 232–241

- Yates LM and Fiedler D 2015 Establishing the stability and reversibility of protein pyrophosphorylation with synthetic peptides. *ChemBiochem* **16** 415–423
- Ye W, Ali N, Bembenek ME, Shears SB and Lafer EM 1995 Inhibition of clathrin assembly by high affinity binding of specific inositol polyphosphates to the synapse-specific clathrin assembly protein AP-3. *J. Biol. Chem.* **270** 1564–1568
- Ye C, Bandara WM and Greenberg ML 2013 Regulation of inositol metabolism is fine-tuned by inositol pyrophosphates in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **288** 24898–24908
- Yoko-o T, Matsui Y, Yagisawa H, Nojima H, Uno I and Toh-e A 1993 The putative phosphoinositide-specific phospholipase C gene, PLC1, of the yeast *Saccharomyces cerevisiae* is important for cell growth. *Proc. Natl. Acad. Sci. USA* **90** 1804–1808
- York JD, Odom AR, Murphy R, Ives EB and Wente SR 1999 A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. *Science* **285** 96–100
- York SJ, Armbruster BN, Greenwell P, Petes TD and York JD 2005 Inositol diphosphate signaling regulates telomere length. *J. Biol. Chem.* **280** 4264–4269
- Zhang Z, Zhao C, Liu B, Liang D, Qin X, Li X, Zhang R, Li C, et al. 2014 Inositol pyrophosphates mediate the effects of aging on bone marrow mesenchymal stem cells by inhibiting Akt signaling. *Stem Cell Res. Ther.* **5** 33

MS received 11 May 2015; accepted 06 July 2015

Corresponding editor: VEENA K PARNAIK